SurvExpress: An Online Biomarker Validation Tool and Database for Cancer Gene Expression Data Using Survival Analysis

Raúl Aguirre‐Gamboa, Hugo Gómez-Rueda, Emmanuel Martínez-Ledesma, Antonio Martínez‐Torteya, Rafael Chacolla-Huaringa, Alberto Rodriguez-Barrientos, José G. Tamez‐Peña, Víctor Treviño · 2013

Read SurvExpress: An Online Biomarker Validation Tool and Database for Cancer Gene Expression Data Using Survival Analysis by Raúl Aguirre‐Gamboa, Hugo Gómez-Rueda, Emmanuel Martínez-Ledesma, Antonio Martínez‐Torteya, Rafael Chacolla-Huaringa, Alberto Rodriguez-Barrientos, José G. Tamez‐Peña, Víctor Treviño (2013) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/openalex-w2037915750.txt.

Introduction

Raul Aguirre-Gamboa, Hugo Gomez-Rueda, Emmanuel Martinez-Ledesma and colleagues built an online tool for cancer gene research. Their paper appeared in PLoS ONE in 2013. Gene signatures may predict cancer outcomes. Testing them across many datasets is slow work. Biologists and doctors needed an easier route.

Their tool, SurvExpress, needs only a list of genes. It holds data from over twenty thousand samples. The data cover more than twenty tissue types. Users can run survival analysis through a web page. The tool compares how well signatures predict outcomes. It also estimates patient risk groups. Fast checks help researchers discard weak signatures early.

Catalog record

CREATORRaúl Aguirre‐Gamboa, Hugo Gómez-Rueda, Emmanuel Martínez-Ledesma, Antonio Martínez‐Torteya, Rafael Chacolla-Huaringa, Alberto Rodriguez-Barrientos, José G. Tamez‐Peña, Víctor Treviño
YEAR2013
COLLECTIONPAPERS
FORMATTXT
FILE SIZE31 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEOpenAlex / PLoS ONE

Source: https://doi.org/10.1371/journal.pone.0074250

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

SurvExpress: An Online Biomarker Validation Tool and Database for Cancer Gene Expression Data Using Survival Analysis Raul Aguirre-Gamboa, Hugo Gomez-Rueda, Emmanuel Martı́nez-Ledesma, Antonio Martı́nez-Torteya, Rafael Chacolla-Huaringa, Alberto Rodriguez-Barrientos, José G. Tamez-Peña, Victor Treviño* Cátedra de Bioinformática, Tecnológico de Monterrey, Monterrey, Nuevo León, México Abstract Validation of multi-gene biomarkers for clinical outcomes is one of the most important issues for cancer prognosis. An important source of information for virtual validation is the high number of available cancer datasets. Nevertheless, assessing the prognostic performance of a gene expression signature along datasets is a difficult task for Biologists and Physicians and also time-consuming for Statisticians and Bioinformaticians. Therefore, to facilitate performance comparisons and validations of survival biomarkers for cancer outcomes, we developed SurvExpress, a cancer-wide gene expression database with clinical outcomes and a web-based tool that provides survival analysis and risk assessment of cancer datasets. The main input of SurvExpress is only the biomarker gene list. We generated a cancer database collecting more than 20,000 samples and 130 datasets with censored clinical information covering tumors over 20 tissues. We implemented a web interface to perform biomarker validation and comparisons in this database, where a multivariate survival analysis can be accomplished in about one minute. We show the utility and simplicity of SurvExpress in two biomarker applications for breast and lung cancer. Compared to other tools, SurvExpress is the largest, most versatile, and quickest free tool available. SurvExpress web can be accessed in http://bioinformatica.mty.itesm.mx/SurvExpress (a tutorial is included). The website was implemented in JSP, JavaScript, MySQL, and R. Citation: Aguirre-Gamboa R, Gomez-Rueda H, Martı́nez-Ledesma E, Martı́nez-Torteya A, Chacolla-Huaringa R, et al. (2013) SurvExpress: An Online Biomarker Validation Tool and Database for Cancer Gene Expression Data Using Survival Analysis. PLoS ONE 8(9): e74250. doi:10.1371/journal.pone.0074250 Editor: William C. S. Cho, Queen Elizabeth Hospital, Hong Kong Received April 21, 2013; Accepted July 31, 2013; Published September 16, 2013 Copyright: ß 2013 Aguirre-Gamboa et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Funding: The authors are thankful for the financial support from Cátedra de Bioinformática CAT220 at ITESM (Tecnológico de Monterrey) and CONACyT grants 83929 and 140601. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Competing Interests: The authors have declared that no competing interests exist. * E-mail: [email protected] complicating and limiting the assessment of multi-gene biomarkers in cancer. Some of the main limitations include considering just one gene at the time or a specific set of genes; focusing on breast or ovarian cancer datasets or to a particular Affymetrix gene expression platform; requiring the upload of Affymetrix gene expression data (.CEL files); and using a single quantity per gene even though some microarray platforms provide more probesets. To solve these issues and to facilitate performance comparisons and validations of prognostic and predictive biomarkers for cancer outcomes, we developed SurvExpress. SurvExpress is a comprehensive gene expression database and web-based tool providing survival analysis and risk assessment in cancer datasets using a biomarker gene list as input. The tool is available in http:// bioinformatica.mty.itesm.mx/SurvExpress. The tool includes a tutorial that describes the analysis options, plots, tables, key concepts related to survival analysis, and representative methods to identify biomarkers from gene expression data. Introduction Cancer causes millions of deaths around the world. To improve treatments, several biomarkers have been proposed for risk prognosis and treatment response. Recent published biomarkers in many types of cancer contain numerous genes and are mainly based on gene expression. They have been generated using microarray profiling and lately by RNA-Seq technologies. Often, identified biomarkers are developed to a specific cancer tissue and subtypes. In breast cancer, for example, more than 40 biomarkers have been proposed containing between 3 and 512 genes and whose prognostic or predictive performance depends on therapy, hormone receptor status, and the number of genes [1,2]. On the other hand, assessing the performance of proposed biomarkers in different populations or evaluating competing biomarkers are difficult tasks even though hundreds of public datasets are available. The main limitations are the time and resources needed for acquiring, processing, normalizing, filtering, and statistical modeling of large gene expression datasets. This is important since several of the reasons involved in the failure of biomarkers in clinical trials are related to data analysis [3]. For the analysis of biomarkers, tools as ITTACA, KMPlot, RecurrenceOnline, bcGeneExMiner, GOBO, and PrognoScan have been proposed [1,4–9]. However, these tools have serious restrictions (Table 1), PLOS ONE | www.plosone.org Materials and Methods Database Acquisition Datasets were obtained mainly from GEO (http://www.ncbi. nlm.nih.gov/geo/) and TCGA (https://tcga-data.nci.nih.gov) after searching for keywords related to cancer, survival, and gene 1 September 2013 | Volume 8 | Issue 9 | e74250 SurvExpress: Biomarker Tool for Clinical Outcomes Table 1. Comparison of survival analysis tools. Tool Genes Per Analysis Tissues Datasets Samples Input Risk Groups KMPlot* 1 2 .30 4,441 AffyID Quartiles ITTACA** 1 7 231 .739 Genes, Groups User Recurrence Online Specific 1 – – CEL Files Specific bc-GenExMiner 1 1 21 3,414 Genes Median PrognoScan 1 14 741 8,626 Genes Algorithm GOBO* Multiple 1 10 1,881 Genes Classifier SurvExpress Multiple 22 142 21,051 Genes Various*** Comparison of survival analysis tools in terms of genes, databases, input, and risk group generation. *Data includes only Affymetrix microarrays. **Only few of the datasets have survival data. ***SurvExpress risk groups can be generated based on the Cox fitting, an optimization algorithm, or user-specified weights. 1 Only including datasets with clinical outcome information. doi:10.1371/journal.pone.0074250.t001 expression technologies. Additionally, a few were obtained from author’s websites and from ArrayExpress (http://www.ebi.ac.uk/ arrayexpress/). The data source used is shown in the web interface. We favored cancer types above two different cohorts and datasets containing survival data over 30 samples in which censoring indicator and time to death, recurrence, relapse, or metastasis were provided. Clinical data was provided by dataset authors via personal email when not available online in corresponding repositories. Datasets were annotated from provider files as found up to September 2012, and were quantilenormalized and log2 transformed when needed. From TCGA, all datasets were obtained at the gene level (level 3). RNA-Seq counts data were log2 transformed. In some cancer types where many datasets were found for the same gene expression platform, we also provide a merged meta-base. In meta-bases, datasets were quantile normalized; probesets means were equalized conserving the standard deviation by each cohort; and datasets were merged by probeset id. At the moment we provide meta-bases for breast, lung, and ovarian cancer. To facilitate gene searches and conversions between gene identifiers, human gene information was used and obtained from the NCBI FTP site (ftp://ftp.ncbi.nih. gov/gene/DATA/GENE_INFO/Mammalia/Homo_sapiens.gene_ info.gz). To simplify the user interface, datasets were grouped by related organ or tissue using disease ontologies [10]. Prognostic Index Estimation The prognostic index (PI), also known as the risk score, is commonly used to generate risk groups. The PI is known as the linear component of the Cox model [11], PI = b1x1+ b2x2+...+bpxp where xi is the expression value and the bI can obtained from the Cox fitting. Each bI can be interpreted as a risk coefficient.

Read the complete text